Peptic ulcer rebleeding risk remains high after endoscopic hemostasis :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Can prophylactic embolization reduce mortality after peptic ulcer rebleeding?

Peptic ulcer bleeding Peptic ulcer bleeding
Peptic ulcer bleeding Peptic ulcer bleeding

What's new?

Recurrent bleeding continues to drive adverse outcomes after peptic ulcer hemorrhage, underscoring the potential role of adjunctive embolization therapy.

Successful endoscopic control of peptic ulcer bleeding does not eliminate the risk of recurrent hemorrhage, which remains a frequent cause of complications and prolonged hospitalization. As clinicians seek strategies to reduce this risk, researchers examined the incidence, predictors, and consequences of rebleeding while evaluating the potential contribution of prophylactic transarterial embolization (pTAE) to patient outcomes.

To better understand post-hemostasis outcomes, investigators evaluated patients treated for peptic ulcer bleeding at a Danish University Hospital over a four-year period. Clinical follow-up extended to one year, enabling assessment of recurrent bleeding, associated complications, and mortality. Patients with high-risk ulcer characteristics were analyzed as a distinct subgroup, while the role of pTAE was explored as a potential strategy to mitigate adverse outcomes.

Among 174 patients treated for peptic ulcer bleeding, recurrent hemorrhage remained a frequent complication despite successful endoscopic hemostasis, with 28% experiencing rebleeding during follow-up. Key findings include:

Rebleeding was significantly associated with:

  1. Low body mass index
  2. Active smoking
  3. Duodenal ulcer location
  4. High-risk Forrest classification (Ia–IIb)
  5. Hypotension at admission

Patients with rebleeding experienced:

  1. Longer hospital stays
  2. Higher rates of adverse clinical events
  3. No significant increase in overall mortality

The predefined high-risk subgroup demonstrated:

  1. Significantly higher rebleeding rates
  2. Higher 90-day mortality
  3. Higher 365-day mortality

Among the 10 patients (6%) who underwent pTAE following initial successful endoscopic hemostasis, rebleeding and mortality rates were similar to those observed in patients who did not receive pTAE. However, a more favorable signal emerged among patients who rebled. Of the 49 subjects with rebleeding, approximately 25% underwent pTAE following a second successful endoscopic intervention.

In this subgroup, one-year mortality was lower in patients receiving pTAE compared with those who did not (17% vs. 43%). The results highlighted recurrent bleeding as a persistent challenge after endoscopic hemostasis, particularly among patients with high-risk ulcer characteristics.

Source:

Scandinavian Journal of Gastroenterology

Article:

Peptic ulcer bleeding and use of transarterial embolization at a center without on-site interventional radiologists: a retrospective cohort study

Authors:

Maria Vestergaard Jensen et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: